Literature DB >> 8380917

HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A.

M Tommasino1, J P Adamczewski, F Carlotti, C F Barth, R Manetti, M Contorni, F Cavalieri, T Hunt, L Crawford.   

Abstract

E7 is the major transforming protein of human papillomavirus type 16 (HPV16). It has been found to associate with the retinoblastoma protein Rb1. We investigated whether HPV16 E7 protein was associated with other cellular proteins, in particular with those involved in cell cycle control. Immunoprecipitates from CaSki cell extracts with an anti E7 monoclonal antibody contained a histone H1 kinase. Recombinant E7, synthesized in yeast, when mixed with protein extracts from epithelial cells bound histone H1 kinase activity in vitro. The in vivo and the in vitro-formed E7-kinase complex had the same periodicity of activity during the cell cycle, being most active in S and G2/M. Immunoblotting of E7 immunoprecipitates with an antibody raised against the p33CDK2, revealed a 33 kDa protein band not detected by an anti-p34cdc2 antibody, suggesting that the E7-associated kinase activity is due to the p33CDK2. The interaction appears to be via cyclin A, since probing of similar immunoblots showed a 50 kDa band corresponding to cyclin A. The association of E7 with cyclin A appeared to be direct, not involving Rb 1 or other proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380917

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 2.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 3.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

4.  Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb.

Authors:  C Neuveut; K G Low; F Maldarelli; I Schmitt; F Majone; R Grassmann; K T Jeang
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

5.  RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication.

Authors:  A Duensing; Y Liu; N Spardy; K Bartoli; M Tseng; J-A Kwon; X Teng; S Duensing
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

6.  Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16.

Authors:  A Schulze; B Mannhardt; K Zerfass-Thome; W Zwerschke; P Jansen-Dürr
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7.

Authors:  Wanxia He; Doug Staples; Clark Smith; Chris Fisher
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors.

Authors:  P Auewarakul; L Gissmann; A Cid-Arregui
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

Review 9.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

Review 10.  A possible role for human papillomaviruses in head and neck cancer.

Authors:  B M Steinberg; T P DiLorenzo
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.